Vertex(VRTX) - 2024 Q3 - Quarterly Results
Vertex(VRTX)2024-11-05 05:02
Vertex Reports Third Quarter 2024 Financial Results — Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — BOSTON -- Vertex Pharmace ...